These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12364937)

  • 1. Interferon beta-1a-induced depression and suicidal ideation in multiple sclerosis.
    Lana-Peixoto MA; Teixeira AL; Haase VG
    Arq Neuropsiquiatr; 2002 Sep; 60(3-B):721-4. PubMed ID: 12364937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report.
    Goëb JL; Cailleau A; Lainé P; Etcharry-Bouyx F; Maugin D; Duverger P; Gohier B; Rannou-Dubas K; Dubas F; Garré JB
    Clin Neuropharmacol; 2003; 26(1):5-7. PubMed ID: 12567157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).
    Durelli L; Verdun E; Barbero P; Bergui M; Versino E; Ghezzi A; Montanari E; Zaffaroni M;
    Lancet; 2002 Apr; 359(9316):1453-60. PubMed ID: 11988242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
    Schott E; Paul F; Wuerfel JT; Zipp F; Rudolph B; Wiedenmann B; Baumgart DC
    World J Gastroenterol; 2007 Jul; 13(26):3638-40. PubMed ID: 17659718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.
    Mohr DC; Likosky W; Dwyer P; Van Der Wende J; Boudewyn AC; Goodkin DE
    Arch Neurol; 1999 Oct; 56(10):1263-5. PubMed ID: 10520943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors leading patients to discontinue multiple sclerosis therapies.
    Daugherty KK; Butler JS; Mattingly M; Ryan M
    J Am Pharm Assoc (2003); 2005; 45(3):371-5. PubMed ID: 15991759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL; Oger J
    Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
    Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
    Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
    Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
    Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent nephrotic syndrome in patient with multiple sclerosis treated with interferon beta-1a.
    Tola MR; Caniatti LM; Gragnaniello D; Russo M; Stabellini N; Granieri E
    J Neurol; 2003 Jun; 250(6):768-9. PubMed ID: 12862038
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute hepatitis secondary to interferon beta-1a in multiple sclerosis.
    Christopher V; Scolding N; Przemioslo RT
    J Neurol; 2005 Jul; 252(7):855-6. PubMed ID: 15742101
    [No Abstract]   [Full Text] [Related]  

  • 13. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Manifestation of Susac syndrome during interferon beta-1a and glatiramer acetate treatment for misdiagnosed multiple sclerosis: a case report.
    Roskal-Wałek J; Biskup M; Dolecka-Ślusarczyk M; Rosołowska A; Jaroszyński A; Odrobina D
    BMC Ophthalmol; 2021 Sep; 21(1):352. PubMed ID: 34592956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review.
    Galetta SL; Markowitz C; Lee AG
    Arch Intern Med; 2002 Oct; 162(19):2161-9. PubMed ID: 12390057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a.
    Almeida L; Neves M; Cardoso E; Melo A
    J Clin Pharm Ther; 2009 Feb; 34(1):125-7. PubMed ID: 19125911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subacute thyroiditis in a patient with MS treated with interferon beta-1a.
    Kreiss Y; Cohen O; Pras E; Achiron A
    Neurology; 1999 Oct; 53(7):1606. PubMed ID: 10534282
    [No Abstract]   [Full Text] [Related]  

  • 18. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis.
    Patten SB; Francis G; Metz LM; Lopez-Bresnahan M; Chang P; Curtin F
    Mult Scler; 2005 Apr; 11(2):175-81. PubMed ID: 15794391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Recommendations for the use of immunomodulatory drugs in multiple sclerosis: the BCTRIMS consensus] [Brazilian Committee for Treatment and Research in Multiple Sclerosis].
    Tilbery CP; Moreira MA; Mendes MF; Lana-Peixoto MA
    Arq Neuropsiquiatr; 2000 Sep; 58(3A):769-76. PubMed ID: 10973126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychiatric side effects of interferon-beta in multiple sclerosis.
    Goeb JL; Even C; Nicolas G; Gohier B; Dubas F; Garré JB
    Eur Psychiatry; 2006 Apr; 21(3):186-93. PubMed ID: 16386408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.